

Thierry Buclin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7486970/publications.pdf>

Version: 2024-02-01

261
papers

14,122
citations

22153

59
h-index

24982

109
g-index

279
all docs

279
docs citations

279
times ranked

14658
citing authors

#	ARTICLE	IF	CITATIONS
1	Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes. <i>Clinical Infectious Diseases</i> , 2008, 46, 201-211.	5.8	823
2	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 13-33.	4.7	781
3	Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. <i>Aids</i> , 2001, 15, 71-75.	2.2	743
4	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , 2002, 359, 30-36.	13.7	635
5	Interindividual Variability of the Clinical Pharmacokinetics of Methadone. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1153-1193.	3.5	510
6	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients. <i>Clinical Cancer Research</i> , 2004, 10, 3728-3736.	7.0	403
7	Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 1-5.	1.5	355
8	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2187-2199.	5.4	321
9	Towards a new combination therapy for tuberculosis with next generation benzothiazinones. <i>EMBO Molecular Medicine</i> , 2014, 6, 372-383.	6.9	311
10	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 20-30.	4.7	231
11	Diet Acids and Alkalis Influence Calcium Retention in Bone. <i>Osteoporosis International</i> , 2001, 12, 493-499.	3.1	205
12	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. <i>Blood</i> , 2011, 117, e75-e87.	1.4	202
13	Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2012, 55, 381-390.	5.8	178
14	Antidepressants for the Treatment of Chronic Pain. <i>Drugs</i> , 2008, 68, 2611-2632.	10.9	173
15	Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 97-112.	2.4	161
16	Renal Drug Transporters and Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2017, 56, 825-892.	3.5	161
17	High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4360-4367.	3.2	147
18	The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double-blind controlled trial. <i>Annals of Oncology</i> , 1999, 10, 1511-1514.	1.2	142

#	ARTICLE	IF	CITATIONS
19	Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools. <i>Clinical Pharmacokinetics</i> , 2013, 52, 9-22.	3.5	141
20	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. <i>Schizophrenia Bulletin</i> , 2018, 44, 317-327.	4.3	121
21	Gender medicine and oncology: report and consensus of an ESMO workshop. <i>Annals of Oncology</i> , 2019, 30, 1914-1924.	1.2	120
22	Label-Free Detection of Tobramycin in Serum by Transmission-Localized Surface Plasmon Resonance. <i>Analytical Chemistry</i> , 2015, 87, 5278-5285.	6.5	115
23	Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 485-494.	4.7	113
24	Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. <i>British Journal of Cancer</i> , 2008, 98, 1633-1640.	6.4	106
25	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 217-230.	1.5	104
26	δ^9 -THC, 11-OH- δ^9 -THC and δ^9 -THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. <i>Forensic Science International</i> , 2001, 123, 159-164.	2.2	102
27	Transplacental passage of protease inhibitors at delivery. <i>Aids</i> , 2002, 16, 889-893.	2.2	102
28	A LC-MS tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1057-1069.	2.3	101
29	Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 259-276.	2.3	100
30	Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. <i>Biomedical Applications</i> , 2000, 740, 43-58.	1.7	99
31	Oligoanalgesia in the Emergency Department: Short-Term Beneficial Effects of an Education Program on Acute Pain. <i>Annals of Emergency Medicine</i> , 2007, 50, 462-471.	0.6	98
32	Effect of dronedarone on renal function in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 070727055311005-???	2.4	96
33	Influence of interferon β -1a dose frequency on PBMC cytokine secretion and biological effect markers. <i>Journal of Neuroimmunology</i> , 1999, 99, 131-141.	2.3	94
34	Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 137-143.	3.2	94
35	Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 463-471.	2.3	94
36	Oral administration of a low dose of midazolam (75 μ g) as an in vivo probe for CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 237-46.	1.9	89

#	ARTICLE	IF	CITATIONS
37	The effect of rectal and nasal administration of salmon calcitonin in normal subjects. <i>Calcified Tissue International</i> , 1987, 41, 252-258.	3.1	88
38	Pharmacokinetics and Pharmacodynamics of IFN- β 1a in Healthy Volunteers. <i>Journal of Interferon and Cytokine Research</i> , 2000, 20, 857-866.	1.2	87
39	Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. <i>European Journal of Endocrinology</i> , 2010, 162, 951-960.	3.7	85
40	Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists. <i>Clinical Pharmacokinetics</i> , 1997, 32, 1-29.	3.5	82
41	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 231-6.	1.9	82
42	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3801-3808.	3.2	82
43	Bioavailability and Biological Efficacy of a New Oral Formulation of Salmon Calcitonin in Healthy Volunteers. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1478-1485.	2.8	79
44	Safe and Effective Variability – A Criterion for Dose Individualization. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 565-568.	2.0	75
45	Pregnancy outcome following maternal exposure to pregabalin may call for concern. <i>Neurology</i> , 2016, 86, 2251-2257.	1.1	75
46	Two cases of "cannabis acute psychosis" following the administration of oral cannabis. <i>BMC Psychiatry</i> , 2005, 5, 17.	2.6	74
47	Influence of perinatal, developmental and environmental factors on cognitive abilities of preterm children without major impairments at 5 years. <i>Early Human Development</i> , 1995, 43, 151-164.	1.8	73
48	Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 599-608.	1.5	73
49	Safety of oral immunisation with recombinant urease in patients with <i>Helicobacter pylori</i> infection. <i>Lancet</i> , The, 1996, 347, 1630-1631.	13.7	72
50	Assessment of Driving Capability Through the Use of Clinical and Psychomotor Tests in Relation to Blood Cannabinoids Levels Following Oral Administration of 20 mg Dronabinol or of a Cannabis Decoction Made with 20 or 60 mg Δ^9 -THC*. <i>Journal of Analytical Toxicology</i> , 2005, 29, 327-338.	2.8	72
51	Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo-controlled trial. <i>Clinical Nutrition</i> , 2006, 25, 418-427.	5.0	72
52	Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. <i>Scientific Reports</i> , 2019, 9, 5078.	3.3	71
53	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 865-873.	1.9	70
54	Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1329-1340.	2.0	67

#	ARTICLE	IF	CITATIONS
55	Functional consequence of MDR1 expression on imatinib intracellular concentrations. <i>Blood</i> , 2003, 102, 1142-1142.	1.4	66
56	Orosomucoid (α 1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 307-318.	4.7	66
57	Disappearance Rate of Catecholamines, Total Metanephrines, and Neuropeptide Y from the Plasma of Patients after Resection of Pheochromocytoma. <i>Clinical Chemistry</i> , 2001, 47, 1075-1082.	3.2	65
58	Valganciclovir in Adult Solid Organ Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 399-418.	3.5	65
59	Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 433-440.	2.3	62
60	Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1717-1728.	2.8	61
61	Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1307-1319.	2.3	60
62	Rate, type, and cost of adverse drug reactions in emergency department admissions. <i>European Journal of Internal Medicine</i> , 2001, 12, 442-447.	2.2	59
63	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. <i>Frontiers in Pharmacology</i> , 2020, 11, 177.	3.5	59
64	Characterization of a Selective Antagonist of Neuropeptide Y at the Y2 Receptor. <i>Journal of Biological Chemistry</i> , 1997, 272, 7699-7706.	3.4	55
65	Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Inpatient Variability. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 394-398.	2.0	52
66	Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction and liquid chromatography-ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 285-292.	2.3	52
67	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1090-1101.	2.4	50
68	Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. <i>Clinical Pharmacokinetics</i> , 2010, 49, 741-765.	3.5	48
69	Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1844-1851.	2.0	48
70	Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 511-522.	2.0	47
71	Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 290-302.	3.0	47
72	Right arm involvement and pain extension can help to differentiate coronary diseases from chest pain of other origin: a prospective emergency ward study of 278 consecutive patients admitted for chest pain. <i>Journal of Internal Medicine</i> , 1990, 227, 165-172.	6.0	46

#	ARTICLE	IF	CITATIONS
73	Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Archives of Orthopaedic and Trauma Surgery, 2011, 131, 657-662.	2.4	45
74	Prevalence and determinants of QT interval prolongation in medical inpatients. Internal Medicine Journal, 2012, 42, 933-940.	0.8	45
75	A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. Journal of Mass Spectrometry, 2013, 48, 616-625.	1.6	45
76	The levels of vancomycin in the blood and the wound after the local treatment of bone and soft-tissue infection with antibiotic-loaded calcium sulphate as carrier material. Bone and Joint Journal, 2017, 99-B, 1537-1544.	4.4	45
77	Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 774, 127-140.	2.3	44
78	Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia, 2007, 21, 1561-1562.	7.2	44
79	Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. Journal of Antimicrobial Chemotherapy, 2004, 54, 269-270.	3.0	43
80	Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 420-429.	2.3	43
81	Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir. Antimicrobial Agents and Chemotherapy, 2009, 53, 3017-3023.	3.2	43
82	Therapeutic Drug Monitoring of Imatinib. Clinical Pharmacokinetics, 2012, 51, 187-201.	3.5	43
83	Association of Patient Sex With Chemotherapy-Related Toxic Effects. JAMA Oncology, 2018, 4, 1003.	7.1	41
84	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 3413-3422.	3.0	40
85	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 2012, 56, 2959-2966.	3.2	39
86	Successful Efavirenz Dose Reduction Guided by Therapeutic Drug Monitoring. Antiviral Therapy, 2011, 16, 189-197.	1.0	38
87	Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT). Journal of Antimicrobial Chemotherapy, 2017, 72, 1462-1465.	3.0	38
88	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.9	38
89	Validation and clinical application of a multiplex high performance liquid chromatography-tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1157, 122160.	2.3	38
90	Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies. Antimicrobial Agents and Chemotherapy, 2009, 53, 785-787.	3.2	37

#	ARTICLE	IF	CITATIONS
91	Large-scale imatinib doseâ€“concentrationâ€“effect study in CML patients under routine care conditions. <i>Leukemia Research</i> , 2014, 38, 764-772.	0.8	37
92	Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3226-3232.	3.2	36
93	Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 150-167.	2.0	36
94	Erlotinib. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 2-21.	2.0	36
95	Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response. <i>Epilepsy Research</i> , 2019, 149, 88-91.	1.6	36
96	Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. <i>Swiss Medical Weekly</i> , 2004, 134, 685-94.	1.6	36
97	Psychopharmacology in supportive care of cancer: a review for the clinician. <i>Supportive Care in Cancer</i> , 2000, 8, 89-97.	2.2	35
98	An ultra performance liquid chromatographyâ€“tandem MS assay for tamoxifen metabolites profiling in plasma: First evidence of 4â€“hydroxylated metabolites in breast cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3402-3414.	2.3	35
99	Imatinib plasma levels: correlation with clinical benefit in GIST patients. <i>British Journal of Cancer</i> , 2010, 102, 1198-1199.	6.4	35
100	Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 568-578.	2.4	35
101	Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2540-2545.	3.0	35
102	Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption. <i>Scientific Reports</i> , 2021, 11, 10493.	3.3	35
103	Sinistrin Clearance for Determination of Glomerular Filtration Rate: A Reappraisal of Various Approaches Using a New Analytical Method. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 679-692.	2.0	33
104	Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. <i>Malaria Journal</i> , 2013, 12, 235.	2.3	33
105	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1007-1018.	2.4	33
106	Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: Relevance to the diagnosis of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 587-593.	1.5	33
107	LCâ€“MS/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: Analytical and clinical validation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 154, 263-277.	2.8	33
108	Pregnancy Outcome Following Maternal Exposure to Mirtazapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 250-259.	1.4	32

#	ARTICLE	IF	CITATIONS
109	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	32
110	Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women. <i>Antiviral Therapy</i> , 2013, 18, 171-182.	1.0	31
111	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	3.0	31
112	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 124-136.	2.3	31
113	Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants. <i>PLoS ONE</i> , 2016, 11, e0158806.	2.5	31
114	Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240, on endocrine and renal functions in healthy volunteers. <i>Journal of Hypertension</i> , 1999, 17, 427-437.	0.5	30
115	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 255-260.	5.7	30
116	Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. <i>Dermatology</i> , 2017, 233, 401-403.	2.1	30
117	Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. <i>Annals of Neurology</i> , 2020, 87, 22-29.	5.3	30
118	Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 52-57.	4.7	29
119	Effect of High- and Low-molecular-weight Low-substituted Hydroxyethyl Starch on Blood Coagulation during Acute Normovolemic Hemodilution in Pigs. <i>Anesthesiology</i> , 2006, 105, 1228-1237.	2.5	29
120	The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 5-13.	11.4	29
121	Multigenerational effects of the anticancer drug tamoxifen and its metabolite 4-hydroxy-tamoxifen on <i>Daphnia pulex</i> . <i>Science of the Total Environment</i> , 2016, 545-546, 21-29.	8.0	29
122	Residual Antimalarials in Malaria Patients from Tanzania – Implications on Drug Efficacy Assessment and Spread of Parasite Resistance. <i>PLoS ONE</i> , 2009, 4, e8184.	2.5	28
123	Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. <i>Aids</i> , 2002, 16, 1982-1983.	2.2	28
124	Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	1.0	28
125	Major depressive disorder in the general hospital: adaptation of clinical practice guidelines. <i>General Hospital Psychiatry</i> , 2003, 25, 185-193.	2.4	27
126	Composition and Cost of Drugs Stored at Home by Elderly Patients. <i>Annals of Pharmacotherapy</i> , 2003, 37, 731-737.	1.9	27

#	ARTICLE	IF	CITATIONS
127	An agenda for UK clinical pharmacology: Monitoring drug therapy. British Journal of Clinical Pharmacology, 2012, 73, 917-923.	2.4	27
128	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. Drug Metabolism and Disposition, 2015, 44, 151-161.	3.3	27
129	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. Journal of Chromatography A, 2014, 1369, 52-63.	3.7	26
130	Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC. Journal of Pharmaceutical and Biomedical Analysis, 2002, 29, 17-33.	2.8	25
131	Angiotensin-Converting Enzyme and Dipeptidyl Peptidase IV Inhibitors. Hypertension, 2009, 54, 468-470.	2.7	25
132	Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. Journal of Antimicrobial Chemotherapy, 2011, 66, 1573-1581.	3.0	25
133	Monoamine Oxidase A Down-Regulation Contributes to High Metanephrine Concentration in Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2773-2781.	3.6	25
134	Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research, 2020, 154, 104278.	7.1	25
135	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Therapeutic Drug Monitoring, 2020, 42, 33-44.	2.0	25
136	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 2013, 23, 9-18.	1.5	25
137	siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. Drug Metabolism Letters, 2010, 4, 114-119.	0.8	24
138	The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on Daphnia pulex in a two-generation study. Science of the Total Environment, 2015, 520, 232-240.	8.0	24
139	Therapeutic drug monitoring of targeted anticancer therapy. Biomarkers in Medicine, 2015, 9, 887-893.	1.4	24
140	Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: Case report, pharmacokinetic modeling, and review of the literature. Hemodialysis International, 2015, 19, 333-343.	0.9	23
141	Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 2690-2697.	3.0	23
142	NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. British Journal of Clinical Pharmacology, 2003, 55, 62-67.	2.4	22
143	Rapid occurrence of depression following addition of sodium oxybate to modafinil. Sleep Medicine, 2010, 11, 500-501.	1.6	22
144	Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncology, The, 2011, 12, 9-11.	10.7	22

#	ARTICLE	IF	CITATIONS
145	How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. <i>Heart</i> , 2011, 97, 1771-1775.	2.9	22
146	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	3.2	22
147	Toxic and drug-induced peripheral neuropathies. <i>Current Opinion in Neurology</i> , 2013, 26, 481-488.	3.6	22
148	Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 159, 341-347.	2.8	22
149	Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4506.	1.6	22
150	Spectrophotometric determination of methylene blue in biological fluids after ion-pair extraction and evidence of its adsorption on plastic polymers. <i>European Journal of Pharmaceutical Sciences</i> , 1997, 5, 335-345.	4.0	21
151	New psycho-pedagogic approach to obesity treatment: A 5-year follow-up. <i>Patient Education and Counseling</i> , 2010, 79, 333-337.	2.2	21
152	Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. <i>BMC Infectious Diseases</i> , 2010, 10, 2.	2.9	21
153	Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 723-727.	1.9	20
154	Are Plasma Levels Valid Surrogates for Cellular Concentrations of Antiretroviral Drugs in HIV-infected Patients?. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 332-338.	2.0	19
155	Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2002, 41, 137-152.	3.5	18
156	Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1332-1335.	3.0	18
157	Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 323-326.	2.9	18
158	Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2613-2615.	3.0	18
159	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	2.2	18
160	'Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients'. <i>Aids</i> , 2001, 15, 1193-1194.	2.2	18
161	Parametric Approaches in Population Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 125-141.	2.0	17
162	Influence of Quinidine on the Pharmacokinetics of Trimipramine and on Its Effect on the Waking EEG of Healthy Volunteers. <i>Neuropsychobiology</i> , 1992, 25, 214-220.	1.9	16

#	ARTICLE	IF	CITATIONS
163	High-performance liquid chromatography of the renal blood flow marker p-aminohippuric acid (PAH) and its metabolite N-acetyl PAH improves PAH clearance measurements. Biomedical Applications, 1997, 703, 25-36.	1.7	16
164	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. PLoS ONE, 2011, 6, e18578.	2.5	16
165	Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Multiple Sclerosis Journal, 2021, 27, 475-478.	3.0	16
166	High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. International Journal of Antimicrobial Agents, 2009, 34, 386-388.	2.5	15
167	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 609-622.	3.3	15
168	Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. British Journal of Clinical Pharmacology, 2017, 83, 2835-2838.	2.4	15
169	Ganciclovir exposure under a 450â€fmg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clinical Transplantation, 2010, 24, 794-800.	1.6	14
170	Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma. PLoS ONE, 2019, 14, e0217139.	2.5	14
171	Effects of MDL 100,240, a Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase on the Vasopressor Response to Exogenous Angiotensin I and Angiotensin II Challenges in Healthy Volunteers. Journal of Cardiovascular Pharmacology, 1998, 31, 408-417.	1.9	14
172	The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. European Journal of Clinical Pharmacology, 1992, 43, 441-443.	1.9	13
173	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 71, 1933-1942.	3.0	13
174	TUCUXI. , 2017, , .		13
175	Levetiracetam circulating concentrations and response in status epilepticus. Epilepsy and Behavior, 2018, 88, 61-65.	1.7	13
176	Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19. Clinical Microbiology and Infection, 2022, 28, 1044-1046.	6.0	13
177	Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. Clinical Pharmacology and Therapeutics, 1991, 49, 665-673.	4.7	12
178	Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. European Journal of Clinical Pharmacology, 2000, 55, 749-754.	1.9	12
179	Novel Starches. Anesthesiology, 2007, 106, 132-143.	2.5	12
180	Referrals of Cancer versus Non-Cancer Patients to A Palliative Care Consult Team: Do They Differ?. Journal of Palliative Care, 2009, 25, 92-99.	1.0	12

#	ARTICLE	IF	CITATIONS
181	Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers. <i>Biological Chemistry</i> , 2011, 392, 217-21.	2.5	12
182	Clindamycin clearance during Cytosorb [®] hemoadsorption: A case report and pharmacokinetic study. <i>International Journal of Artificial Organs</i> , 2019, 42, 258-262.	1.4	12
183	Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	12
184	Guidance to develop individual dose recommendations for patients on chronic hemodialysis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 737-752.	3.1	11
185	Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?. <i>Epilepsy and Behavior</i> , 2017, 74, 41-44.	1.7	11
186	Pharmacokinetic interaction between methotrexate and chloral hydrate. <i>Pediatric Blood and Cancer</i> , 2013, 60, 518-520.	1.5	10
187	Perampanel: A Significant Liver Enzyme Inducer in Some Patients?. <i>European Neurology</i> , 2014, 72, 213-216.	1.4	10
188	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
189	Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution. <i>Neuromuscular Disorders</i> , 2018, 28, 865-867.	0.6	10
190	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121733.	2.3	10
191	Compassionate Use of Letemovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 96-99.	1.3	10
192	Estimation of Glomerular Filtration Rate by Sinistrin Clearance Using Various Approaches. <i>Renal Failure</i> , 1998, 20, 267-276.	2.1	9
193	The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 435-442.	1.9	9
194	Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with <i>Aspergillus pneumonia</i> . <i>Aids</i> , 2012, 26, 776-778.	2.2	9
195	Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH. <i>Drug Metabolism Letters</i> , 2020, 13, 102-110.	0.8	9
196	No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent. <i>Journal of Applied Physiology</i> , 2021, 130, 226-236.	2.5	9
197	Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 263.	2.0	9
198	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts'™ Discussion on Use, Strengths, and Limitations. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 158-170.	2.0	9

#	ARTICLE	IF	CITATIONS
199	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. <i>Chimia</i> , 2012, 66, 291-295.	0.6	8
200	Seizure freedom and plasma levels of newer generation antiseizure medications. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 202-208.	2.1	8
201	Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00558.	2.4	8
202	Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 226-228.	1.0	7
203	Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data. <i>International Journal of Hematology</i> , 2013, 97, 299-300.	1.6	7
204	Tobramycin exposure from active calcium sulfate bone graft substitute. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 12.	2.4	7
205	Cascaded PID controller for anaesthesia delivery. , 2016, 2016, 533-536.		7
206	Robustness analysis of personalised delivery rate computation for IV administered anesthetic. <i>Smart Health</i> , 2018, 9-10, 101-114.	3.2	7
207	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2022-2032.	2.4	7
208	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz464.	0.9	7
209	Impact of the C2/C6 Ratio of High-molecular-weight Hydroxyethyl Starch on Pharmacokinetics and Blood Coagulation in Pigs. <i>Anesthesiology</i> , 2007, 107, 442-451.	2.5	7
210	A case of voluntary intoxication with efavirenz and lamivudine. <i>Aids</i> , 2006, 20, 1352-1354.	2.2	6
211	Cliptins. <i>Lancet</i> , The, 2007, 369, 269.	13.7	6
212	Is Dipeptidylpeptidase IV the Missing Link in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema?. <i>Hypertension</i> , 2008, 51, 45-47.	2.7	6
213	Imipenem underdosing as a cause of persistent neutropenic fever?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 665-667.	3.0	6
214	Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!. <i>Frontiers in Pediatrics</i> , 2021, 9, 768438.	1.9	6
215	Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	1.0	6
216	The importance of assessing the dose actually administered in pharmacokinetic trials. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 235-240.	4.7	5

#	ARTICLE	IF	CITATIONS
217	A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 331-341.	2.3	5
218	Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1037-1048.	3.5	5
219	Case Report: Colchicine Toxicokinetic Analysis in a Poisoned Child Requiring Extracorporeal Life Support. <i>Frontiers in Pediatrics</i> , 2021, 9, 658347.	1.9	5
220	Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac043.	2.1	5
221	Trace lithium in mood disorders. <i>Journal of Affective Disorders</i> , 1999, 54, 199-203.	4.1	4
222	NPY Y1 receptor is not involved in the hemodynamic response to an acute cold pressor test in mice. <i>Peptides</i> , 2007, 28, 315-319.	2.4	4
223	Pharmacovigilance in pregnancy: adverse drug reactions associated with fetal disorders. <i>Journal of Perinatal Medicine</i> , 2013, 41, 301-307.	1.4	4
224	Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. <i>American Journal of Kidney Diseases</i> , 2017, 69, 553-554.	1.9	4
225	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 379-390.	3.5	4
226	Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2022, 94, 66-69.	2.0	4
227	Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, , .	2.5	4
228	Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response. <i>European Journal of Neurology</i> , 0, , .	3.3	4
229	Effect of dronedarone on renal function in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, P10-P10.	4.7	3
230	Calibration of Fractionated Metanephrines in Urine: Still an Issue?. <i>Clinical Chemistry</i> , 2008, 54, 1738-1739.	3.2	3
231	Ethical approval for multicenter cohort studies on drug exposure during pregnancy: A survey among members of the European Network of Teratology Information Services (ENTIS). <i>Reproductive Toxicology</i> , 2018, 80, 68-72.	2.9	3
232	Sub-picomolar quantification of PTH 1-34 in plasma by UHPLC-MS/MS after subcutaneous injection of teriparatide and identification of PTH 1-33, its degradation product. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 205-212.	2.8	3
233	Specific Determination of PAH and Its N-Acetyl Metabolite by HPLC Increases the Accuracy and Precision of PAH Clearance Measurements. <i>Renal Failure</i> , 1998, 20, 311-317.	2.1	2
234	A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine. <i>Transplantation Proceedings</i> , 2001, 33, 2557-2562.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Pharmacokinetic and pharmacodynamic profile of icatibant. Clinical Pharmacology and Therapeutics, 2004, 75, P56.	4.7	2
236	Reply to Zong et al.. Leukemia, 2007, 21, 1563-1564.	7.2	2
237	A Pain in the Neck. Clinical Chemistry, 2013, 59, 1280-1281.	3.2	2
238	Pharmacokinetics in hepatic impairment: Mind the protein binding. Journal of Hepatology, 2015, 63, 1539-1540.	3.7	2
239	Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication. International Journal of Antimicrobial Agents, 2015, 45, 325-327.	2.5	2
240	Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Therapeutic Drug Monitoring, 2016, 38, 506-515.	2.0	2
241	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Cancer Chemotherapy and Pharmacology, 2017, 79, 215-218.	2.3	2
242	N-acetyl-cysteine in a double-blind randomized placebo-controlled trial: Towards biomarker guided treatment in early psychosis. European Psychiatry, 2017, 41, s806-s806.	0.2	2
243	Sensitive quantification of the somatostatin analog AP102 in plasma by ultra-high pressure liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study in rats. Drug Testing and Analysis, 2018, 10, 1448-1457.	2.6	2
244	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology, 2021, 77, 979-987.	1.9	2
245	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2
246	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	2
247	Type 1 IFNs in human versus mouse. Nature Immunology, 2000, 1, 265-265.	14.5	1
248	The bradykinin antagonist icatibant increases electrolyte and water excretion after sodium challenge in patients with liver cirrhosis. Clinical Pharmacology and Therapeutics, 2004, 75, P12.	4.7	1
249	Adaptation of clinical practice guidelines on major depressive disorders in the general hospital: An update. Journal of Psychosomatic Research, 2009, 66, 353-354.	2.6	1
250	Authors' response to: Statins in pregnancy: safety and perspectives of therapeutic applications. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1440-1440.	2.3	1
251	Methods for Personalised Delivery Rate Computation for IV Administered Anesthetic Propofol. Computational Biology, 2019, , 369-397.	0.2	1
252	Icatibant has no impact on renal function in healthy subjects. Clinical Pharmacology and Therapeutics, 2004, 75, P57.	4.7	0

#	ARTICLE	IF	CITATIONS
253	34 Pharmacokinetic and pharmacodynamic evaluation of valganciclovir in solid organ transplant patients. International Journal of Infectious Diseases, 2006, 10, S19.	3.3	0
254	"iatrogenicity cascade": Doing harm by treating harm?. Wiener Medizinische Wochenschrift, 2009, 159, 53-57.	1.1	0
255	Response to Díaz and de Leon "The Mathematics of Drug Dose Individualization Should be Built With Random Effects Linear Models". Therapeutic Drug Monitoring, 2013, 35, 873-874.	2.0	0
256	Biases affecting injected doses of an experimental drug during clinical trials. Trials, 2016, 17, 321.	1.6	0
257	Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: A case report. Reproductive Toxicology, 2017, 72, 214-215.	2.9	0
258	F44. AN ADD-ON TRIAL WITH N-ACETYL-CYSTEINE (NAC) IN EARLY PSYCHOSIS PATIENTS: TOWARDS BIOMARKER GUIDED TREATMENT. Schizophrenia Bulletin, 2018, 44, S236-S236.	4.3	0
259	Trastuzumab versus MYL-1401O (a proposed trastuzumab biosimilar) in a phase I bioequivalence study: In vivo and in vitro immunomodulation.. Journal of Clinical Oncology, 2017, 35, 10-10.	1.6	0
260	Evaluation of Exposure to Vancomycin in Neonates with Current Dosing Approaches. SSRN Electronic Journal, 0, , .	0.4	0
261	Pharmacovigilance, h�movigilance, vaccinovigilance, t�ratovigilance����: quelles retomb�es impr�vues pour les patients, les intervenants de sant� et les syst�mes de soins�. Anthropologie & Sant�, 2019, , .	0.2	0